Homozygous deletion of FMS in a patient with the 5q- syndrome.

Homozygous deletion of FMS in a patient with the 5q- syndrome.

Opis bibliograficzny
Główni autorzy:	Boultwood, J, Rack, K, Buckle, V, Kelly, S, Madden, J, Oscier, D, Wainscoat, J
Format:	Journal article
Język:	English
Wydane:	1990

Podobne zapisy

Loss of both CSF1R (FMS) alleles in patients with myelodysplasia and a chromosome 5 deletion.
od: Boultwood, J, i wsp.
Wydane: (1991)

Hematological features of patients with myelodysplastic syndromes associated with a chromosome 5q deletion.
od: Lewis, S, i wsp.
Wydane: (1995)

MOLECULAR MAPPING OF UNCHARACTERISTICALLY SMALL 5Q DELETIONS IN 2 PATIENTS WITH THE 5Q- SYNDROME - DELINEATION OF THE CRITICAL REGION ON 5Q AND IDENTIFICATION OF A 5Q- BREAKPOINT
od: Boultwood, J, i wsp.
Wydane: (1993)

Molecular mapping of uncharacteristically small 5q deletions in two patients with the 5q- syndrome: delineation of the critical region on 5q and identification of a 5q- breakpoint.
od: Boultwood, J, i wsp.
Wydane: (1994)

Structure of the granulocyte macrophage colony-stimulating factor gene in patients with the myelodysplastic syndromes.
od: Boultwood, J, i wsp.
Wydane: (1990)

Allelic loss of IRF1 in myelodysplasia and acute myeloid leukemia: retention of IRF1 on the 5q- chromosome in some patients with the 5q- syndrome.
od: Boultwood, J, i wsp.
Wydane: (1993)

Clonality of cell populations in refractory anaemia using combined approach of gene loss and X-linked restriction fragment length polymorphism-methylation analyses.
od: Abrahamson, G, i wsp.
Wydane: (1991)

MOLECULAR DELINEATION OF THE CRITICAL REGION OF THE 5Q-CHROMOSOME IN THE 5Q-SYNDROME
od: Boultwood, J, i wsp.
Wydane: (1993)

MOLECULAR MAPPING OF THE 7Q-DELETION IN MYELOID DISORDERS
od: Lewis, S, i wsp.
Wydane: (1993)

The 5q-syndrome.
od: Boultwood, J, i wsp.
Wydane: (1994)

5q- syndrome.
od: Boultwood, J, i wsp.
Wydane: (2012)

Narrowing the critical deleted region in the 5q-syndrome.
od: Jaju, R, i wsp.
Wydane: (1996)

Narrowing and genomic annotation of the commonly deleted region of the 5q- syndrome.
od: Boultwood, J, i wsp.
Wydane: (2002)

The 5q- syndrome.
od: Giagounidis, A, i wsp.
Wydane: (2004)

Molecular cytogenetic delineation of the critical deleted region in the 5q- syndrome.
od: Jaju, R, i wsp.
Wydane: (1998)

Advances in the 5q- syndrome.
od: Boultwood, J, i wsp.
Wydane: (2010)

Lineage studies of 5q deletions using combined immunophenotyping and fish.
od: Jaju, R, i wsp.
Wydane: (1999)

Lenalidomide selectively inhibits in vitro growth of the malignant clone in myelodysplastic syndrome (MDS) patients with 5q deletion.
od: Jadersten, M, i wsp.
Wydane: (2005)

Expression profiling of CD34+cells in patients with myelodysplastic syndromes with and without a del(5q)
od: Pellagatti, A, i wsp.
Wydane: (2005)

Molecular characterization of the 7q deletion in myeloid disorders.
od: Lewis, S, i wsp.
Wydane: (1996)

Molecular diagnosis of the 5q deletion in malignant myeloid disorders.
od: Boultwood, J
Wydane: (1996)

Expression profiling of CD34+cells in patients with myelodysplastic syndromes with and without a del(5q).
od: Pellagatti, A, i wsp.
Wydane: (2004)

The human POP2 gene: identification, sequencing, and mapping to the critical region of the 5q- syndrome.
od: Fidler, C, i wsp.
Wydane: (1999)

Haploinsufficiency of ribosomal proteins and p53 activation in anemia: Diamond-Blackfan anemia and the 5q- syndrome.
od: Boultwood, J, i wsp.
Wydane: (2012)

Lenalidomide up-regulates SPARC and inhibits in vitro growth of the malignant clone in myelodysplastic syndrome patients with 5q deletion.
od: Pellagatti, A, i wsp.
Wydane: (2006)

Combined immunophenotyping and FISH identifies the involvement of B-cells in 5q- syndrome.
od: Jaju, R, i wsp.
Wydane: (2000)

Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q- syndrome patients.
od: Pellagatti, A, i wsp.
Wydane: (2007)

Telomere length in myelodysplastic syndromes.
od: Boultwood, J, i wsp.
Wydane: (1997)

NRAS, FLT3 and TP53 mutations in patients with myelodysplastic syndrome and a del(5q).
od: Fidler, C, i wsp.
Wydane: (2004)

ISOLATION OF NOVEL CDNA CLONES MAPPING TO THE CRITICAL REGION OF THE 5Q-CHROMOSOME IN THE 5Q-SYNDROME
od: Boultwood, J, i wsp.
Wydane: (1994)

Molecular analysis of the 5q-syndrome
od: Boultwood, J
Wydane: (2007)

Physical mapping of the human ATX1 homologue (HAH1) to the critical region of the 5q- syndrome within 5q32, and immediately adjacent to the SPARC gene.
od: Boultwood, J, i wsp.
Wydane: (2000)

Activation of the mTOR pathway by the amino acid (L)-leucine in the 5q- syndrome and other ribosomopathies.
od: Boultwood, J, i wsp.
Wydane: (2013)

Narrowing and genomic annotation of the critical region of the 5q-syndrome.
od: Boultwood, J, i wsp.
Wydane: (2000)

PB1912: MYELODYSPLASTIC SYNDROME WITH ISOLATED 5Q DELETION AND ASSOCIATED 5Q DELETION TO 13Q DELETION
od: N. Bouayed Abdelmoula, i wsp.
Wydane: (2022-06-01)

Genes located within the del(9q) commonly deleted region are down-regualted in acute myeloid leukaemia.
od: Zhao, Z, i wsp.
Wydane: (2004)

Molecular characterization of the chromosome 9q deletion in AML.
od: Side, L, i wsp.
Wydane: (2000)

Physical and transcriptional characterization of the commonly deleted region in del(9q) AML.
od: Daly, S, i wsp.
Wydane: (2001)

Gene expression profiling in patients with myelodysplastic syndromes, including patients with the del(5q)
od: Boultwood, J
Wydane: (2009)

Practical considerations in the analysis of chromosomal deletion breakpoints by pulsed field gel electrophoresis.
od: Abrahamson, G, i wsp.
Wydane: (1991)